You are currently viewing a new version of our website. To view the old version click .

Most Recent

  • Proceeding Paper
  • Open Access
335 Views
10 Pages

Antibody–drug conjugates (ADCs) represent a novel and rapidly evolving class of targeted therapeutics that combine the high specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs. These engineered...

  • Proceeding Paper
  • Open Access
166 Views
8 Pages

Radiolabeled monoclonal antibodies represent a promising approach to integrate molecular imaging with immunotherapy for cancer diagnosis and treatment. These antibodies target immune checkpoints and tumor-associated antigens, enabling non-invasive vi...

  • Conference Report
  • Open Access
520 Views
44 Pages

Abstracts of the 2025 International Kidney Cancer Symposium (IKCS) Europe

  • Axel Bex,
  • Ignacio Durán,
  • Salvatore La Rosa and
  • Lisa Pickering

The 2025 International Kidney Cancer Symposium—Europe (IKCSEU25) was held in Amsterdam, the Netherlands, from 1 to 3 May 2025, organized by the Kidney Cancer Association (KCA). This annual event serves as the premier European meeting dedicated...

  • Proceeding Paper
  • Open Access
307 Views
5 Pages

The Importance of Multidisciplinary Team Meetings (MDMs) with Focus on Minimal Surgery

  • Lars Lund,
  • Else Helene Ibfelt,
  • Heidi Larsson,
  • Niels Fristrup,
  • Anne Kirstine Møller Darras and
  • Mette Nørgaard

Since 2010, all Danish departments treating renal cell carcinoma (RCC) have reported to the national quality database, enabling systematic auditing of outcomes. Using the unique Civil Registration Number, data are linked to national registries, ensur...

  • Proceeding Paper
  • Open Access
426 Views
10 Pages

First Interim Analysis of the CABONEXT Study: A Retrospective Evaluation of Treatment Patterns Following Cabozantinib Treatment for Advanced Renal Cancer

  • Simon Nannini,
  • Fabien Moinard-Butot,
  • Sylvain Ladoire,
  • Dorian Bochaton,
  • Pierre Bigot,
  • Félix Lefort,
  • Hakim Mahammedi,
  • Fabien Calcagno,
  • Jean-Baptiste Barbe Richaud and
  • Luca Campedel
  • + 5 authors

The CABONEXT study is the first multicenter retrospective analysis evaluating subsequent systemic therapies after cabozantinib-based treatment in metastatic renal cell carcinoma (mRCC). This interim analysis includes 77 patients receiving subsequent...

  • Proceeding Paper
  • Open Access
518 Views
5 Pages

Background: Artificial intelligence (AI) has the potential to significantly enhance clinical decision-making in oncology. However, its application in renal cell carcinoma (RCC) remains limited. The ART (Artificial Intelligence in Renal Tumors) projec...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Med. Sci. Forum - ISSN 2673-9992